Acute Stroke Patients With Depression

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Rocket Pharmaceuticals
1 program
Group-based Acceptance and Commitment TherapyN/A1 trial
Active Trials
NCT05727358Completed139Est. Aug 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rocket PharmaceuticalsGroup-based Acceptance and Commitment Therapy

Clinical Trials (1)

Total enrollment: 139 patients across 1 trials

NCT05727358Rocket PharmaceuticalsGroup-based Acceptance and Commitment Therapy

Effectiveness of Group Acceptance and Commitment Therapy in Treating Acute Stroke Patients With Depression

Start: Aug 2018Est. completion: Aug 2021139 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)